TY - JOUR
T1 - Characterization of Streptococcus pneumoniae detected in clinical respiratory tract samples in southern Sweden 2 to 4 years after introduction of PCV13
AU - Uddén, Fabian
AU - Rünow, Elisabeth
AU - Slotved, Hans Christian
AU - Fuursted, Kurt
AU - Ahl, Jonas
AU - Riesbeck, Kristian
PY - 2021/8
Y1 - 2021/8
N2 - Objective: To determine the serotype distribution and antimicrobial resistance of Streptococcus pneumoniae associated with mucosal infections in patients of all ages, 2 to 4 years after the transition from a 10-valent pneumococcal conjugate vaccine (PCV10) to PCV13 in the childhood immunization programme. Methods: Background information and antimicrobial susceptibility data regarding all respiratory tract, middle ear, and conjunctival samples positive for growth of S. pneumoniae (n = 2,131) were collected during 18 months in 2016–2018. Available corresponding bacterial isolates were serotyped by PCR and/or antisera (n = 1,858). Results: In total, 17% of isolates were covered by PCV13, predominantly represented by serotypes 3 (9%) and 19A (5%). The most common nonvaccine serotypes were 11A (10%), 23B (10%), 15A (6%) and 35F (5%). Isolates exhibiting serotype 15A or 23B were often multidrug-resistant (21%) or penicillin nonsusceptible (38%), respectively. Conclusions: The overall proportion of serotype 19A was halved compared to a previous observation period when PCV10 was used (years 2011–2013), suggesting herd protection related to PCV13. The proportion of serotype 3 was, however, unchanged. Despite most nonvaccine serotypes causing mucosal infections have a low invasive potential, certain antibiotic resistant serotypes may pose a clinical problem.
AB - Objective: To determine the serotype distribution and antimicrobial resistance of Streptococcus pneumoniae associated with mucosal infections in patients of all ages, 2 to 4 years after the transition from a 10-valent pneumococcal conjugate vaccine (PCV10) to PCV13 in the childhood immunization programme. Methods: Background information and antimicrobial susceptibility data regarding all respiratory tract, middle ear, and conjunctival samples positive for growth of S. pneumoniae (n = 2,131) were collected during 18 months in 2016–2018. Available corresponding bacterial isolates were serotyped by PCR and/or antisera (n = 1,858). Results: In total, 17% of isolates were covered by PCV13, predominantly represented by serotypes 3 (9%) and 19A (5%). The most common nonvaccine serotypes were 11A (10%), 23B (10%), 15A (6%) and 35F (5%). Isolates exhibiting serotype 15A or 23B were often multidrug-resistant (21%) or penicillin nonsusceptible (38%), respectively. Conclusions: The overall proportion of serotype 19A was halved compared to a previous observation period when PCV10 was used (years 2011–2013), suggesting herd protection related to PCV13. The proportion of serotype 3 was, however, unchanged. Despite most nonvaccine serotypes causing mucosal infections have a low invasive potential, certain antibiotic resistant serotypes may pose a clinical problem.
KW - Antimicrobial resistance
KW - Epidemiology
KW - Respiratory tract infection
KW - Serotype
KW - Streptococcus pneumoniae
U2 - 10.1016/j.jinf.2021.05.031
DO - 10.1016/j.jinf.2021.05.031
M3 - Journal article
C2 - 34062179
AN - SCOPUS:85107883113
SN - 0163-4453
VL - 83
SP - 190
EP - 196
JO - Journal of Infection
JF - Journal of Infection
IS - 2
ER -